NanoRepro buys out ALPHABIOL partner for €25K to build third business pillar
What's the deal? German consumer health company NanoReproDealroom has a profile for this one. Try Dealroom → has acquired the remaining 67% of hyped about science GmbHDealroom has a profile for this one. Try Dealroom →, in which it already held a 33% equity stake. It paid €25,000 and transferred its Phlas brand and associated product to terraplasma GmbHDealroom has a profile for this one. Try Dealroom →, the previous co-owner.
What's it buying? The deal gives NanoRepro full control of the ALPHABIOLDealroom has a profile for this one. Try Dealroom → nutritional elixirs brand, held within the now wholly owned company that is set to be renamed ALPHABIOL GmbH. The target holds €1.0m of capital and the ALPHABIOL brand and products, valued at €2.5m in total, according to analyst estimates.
Why now? ALPHABIOL was moved out of NanoRepro into the hyped about science ecosystem in the first quarter of 2026 to be combined with luxury product Phlas. This step reverses that logic, separating the two brands so each can run under a cleaner, independent strategy.
What's the endgame? NanoRepro will now rest on three defined pillars: rapid testing kits, PAEDIPROTECTDealroom has a profile for this one. Try Dealroom →, and ALPHABIOL. These are complemented by a roughly 44% stake in DKW (newkee)Dealroom has a profile for this one. Try Dealroom → and a smaller holding in FibreSenseDealroom has a profile for this one. Try Dealroom →.
ALPHABIOL is a small but growing pillar, built on FY25 revenues of €0.5m and an estimated 8.6% compound annual growth rate through FY30.
By the numbers: Consolidating hyped about science from FY26e, analysts expect group sales of €19m, up 18.7% year on year, and EBITDA of €-0.3m — a marked improvement on the €-1.7m estimated for FY25. Notably, the terms imply no write-down of asset value at NanoRepro.
Management is expected to keep scaling its multi-brand consumer health platform while cutting costs, including finance and back-office harmonisation from the fourth quarter of 2026 under incoming chief financial officer Mike Eckel, and logistics centralisation in Kirchhain. That is expected to lift the EBITDA margin from -11% in FY25 to 5% in FY27e.
The signal: The buyout shows NanoRepro tidying up a sprawling portfolio into distinct, independently managed brands. By separating ALPHABIOL from Phlas and giving each a dedicated vehicle, the company is betting that a cleaner structure will help it push its consumer health platform toward profitability.
Read more: wallstreet-online.de
Image credit: shannonkringen
